Medicare to crack down on PBM 'lock-in'

The federal agency that manages Medicare said Tuesday it had finalized a rule meant to curb an industry practice that has inflated drug costs for some patients with Medicare drug coverage. Report

Suggested Articles


After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.